Study S001919

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise

ClinicalTrials.gov record

Registration

Registration: NCT05628311
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 319
Start: 2023-01-06
Primary completion: 2023-10-25
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Type 2 Diabetes
Interventions: OTHER:placebo; DRUG:IBI362
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c change from baseline at week 24 [Baseline, 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.